The World Health Organization (WHO) has escalated its risk assessment of the Bundibugyo strain of Ebola, warning that the likelihood of a national outbreak in the Democratic Republic of Congo (DRC) is now “very high”.
The strain, for which there is currently no approved vaccine or treatment, was declared a public health emergency of international concern by the WHO on Sunday, underscoring the seriousness of the evolving situation.
“We are now revising our risk assessment to very high at the national level, high at the regional level, and low at global level,” WHO Director-General Tedros Adhanom Ghebreyesus told reporters.
According to the WHO, 82 confirmed cases have been recorded in the DRC, including seven confirmed deaths. In addition, authorities have reported 177 suspected deaths and nearly 750 suspected cases, raising fears that the outbreak may be significantly larger than currently documented.
The situation in neighbouring Uganda remains comparatively stable, with two confirmed cases—both linked to travel from the DRC. One of those cases was fatal, Tedros noted.
WHO officials have warned that the virus’ transmission potential is particularly concerning. “The potential of this virus spreading rapidly is high, very high, and that changed the whole dynamic,” said Abdirahman Mahamud, WHO Director of Health Emergency Alert and Response Operations.
Containment measures introduced in Uganda, including intensified contact tracing and the cancellation of a mass gathering, are believed to be helping to slow transmission, according to the WHO chief.
International concern has also grown following reports that a United States national working in the DRC has tested positive for Ebola and was transferred to Germany for specialised treatment. The WHO further indicated that another American national, identified as a high-risk contact, has reportedly been moved to the Czech Republic for monitoring.
In response to the outbreak, WHO Chief Scientist Dr Sylvie Briand said an experimental antiviral, Obeldesivir, an oral drug originally developed by Gilead Sciences for COVID-19, could potentially be deployed among Ebola contacts as a preventive measure. However, she stressed that its use would be subject to strict clinical protocols.
While the WHO says early surveillance efforts are beginning to identify more cases, officials caution that the outbreak likely began around two months ago before being formally declared last week, meaning response systems are now working to catch up with the spread.
Health authorities continue to intensify monitoring and containment efforts as concerns grow over the scale and trajectory of the outbreak across Central Africa.




